Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 1
2017 1
2018 1
2019 4
2020 4
2021 4
2022 5
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Membranous Nephropathy - PLA2R Induced"
Page 1
Membranous nephropathy.
Ronco P, Beck L, Debiec H, Fervenza FC, Hou FF, Jha V, Sethi S, Tong A, Vivarelli M, Wetzels J. Ronco P, et al. Nat Rev Dis Primers. 2021 Sep 30;7(1):69. doi: 10.1038/s41572-021-00303-z. Nat Rev Dis Primers. 2021. PMID: 34593809 Review.
Membranous nephropathy (MN) is a glomerular disease that can occur at all ages. ...MN is an autoimmune disease characterized by a thickening of the glomerular capillary walls due to immune complex deposition. Identification of the phospholipase A2 receptor (PLA2R …
Membranous nephropathy (MN) is a glomerular disease that can occur at all ages. ...MN is an autoimmune disease characterized b …
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, Jefferson JA, Gipson PE, Rizk DV, Sedor JR, Simon JF, McCarthy ET, Brenchley P, Sethi S, Avila-Casado C, Beanlands H, Lieske JC, Philibert D, Li T, Thomas LF, Green DF, Juncos LA, Beara-Lasic L, Blumenthal SS, Sussman AN, Erickson SB, Hladunewich M, Canetta PA, Hebert LA, Leung N, Radhakrishnan J, Reich HN, Parikh SV, Gipson DS, Lee DK, da Costa BR, Jüni P, Cattran DC; MENTOR Investigators. Fervenza FC, et al. N Engl J Med. 2019 Jul 4;381(1):36-46. doi: 10.1056/NEJMoa1814427. N Engl J Med. 2019. PMID: 31269364 Clinical Trial.
BACKGROUND: B-cell anomalies play a role in the pathogenesis of membranous nephropathy. B-cell depletion with rituximab may therefore be noninferior to treatment with cyclosporine for inducing and maintaining a complete or partial remission of proteinuria in …
BACKGROUND: B-cell anomalies play a role in the pathogenesis of membranous nephropathy. B-cell depletion with rituximab may th …
The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.
Fernández-Juárez G, Rojas-Rivera J, Logt AV, Justino J, Sevillano A, Caravaca-Fontán F, Ávila A, Rabasco C, Cabello V, Varela A, Díez M, Martín-Reyes G, Diezhandino MG, Quintana LF, Agraz I, Gómez-Martino JR, Cao M, Rodríguez-Moreno A, Rivas B, Galeano C, Bonet J, Romera A, Shabaka A, Plaisier E, Espinosa M, Egido J, Segarra A, Lambeau G, Ronco P, Wetzels J, Praga M; STARMEN Investigators. Fernández-Juárez G, et al. Kidney Int. 2021 Apr;99(4):986-998. doi: 10.1016/j.kint.2020.10.014. Epub 2020 Nov 7. Kidney Int. 2021. PMID: 33166580 Free article. Clinical Trial.
This was tested in a randomized, open-label controlled trial of 86 patients with primary membranous nephropathy and persistent nephrotic syndrome after six-months observation and assigned 43 each to receive six-month cyclical treatment with corticoster …
This was tested in a randomized, open-label controlled trial of 86 patients with primary membranous nephropathy …
New-Onset and Relapsed Membranous Nephropathy post SARS-CoV-2 and COVID-19 Vaccination.
Ma Q, Li X, Xu G. Ma Q, et al. Viruses. 2022 Sep 28;14(10):2143. doi: 10.3390/v14102143. Viruses. 2022. PMID: 36298697 Free PMC article. Review.
Since the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak and COVID-19 vaccination, new-onset and relapsed clinical cases of membranous nephropathy (MN) have been reported. However, their clinical characteristics and pathogenesis …
Since the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak and COVID-19 vaccination, new-onset and relapsed clinical …
Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study.
Zhang S, Huang J, Dong J, Li Z, Sun M, Sun Y, Chen B. Zhang S, et al. Front Immunol. 2023 Apr 28;14:1156470. doi: 10.3389/fimmu.2023.1156470. eCollection 2023. Front Immunol. 2023. PMID: 37187749 Free PMC article.
BACKGROUND: Rituximab (RTX) is gaining increasing clinical acceptance in the treatment of primary membranous nephropathy (PMN), with demonstrated efficacy and safety. ...Anti-PLA2R antibodies can be used as a marker for RTX treatment monitoring, and an …
BACKGROUND: Rituximab (RTX) is gaining increasing clinical acceptance in the treatment of primary membranous nephropathy …
Immunosuppressive Therapy in Primary Membranous Nephropathy with Compromised Renal Function.
Ramachandran R, Prabakaran R, Priya G, Nayak S, Kumar P, Kumar A, Kumar V, Agrawal N, Rathi M, Kohli HS, Nada R. Ramachandran R, et al. Nephron. 2022;146(2):138-145. doi: 10.1159/000518609. Epub 2021 Nov 3. Nephron. 2022. PMID: 34818240
INTRODUCTION: Renal dysfunction at presentation is uncommon in primary membranous nephropathy (PMN). The data on the outcome of PMN patients with renal dysfunction at outset are scarce. ...Eight (12.5%) had progressed to end-stage renal disease at the last follow-up …
INTRODUCTION: Renal dysfunction at presentation is uncommon in primary membranous nephropathy (PMN). The data on the outcome o …
Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels.
Xue C, Wang J, Pan J, Liang C, Zhou C, Wu J, Song S, Cui L, Zhang L, Liu Y, Dai B. Xue C, et al. BMC Nephrol. 2023 Sep 22;24(1):280. doi: 10.1186/s12882-023-03307-x. BMC Nephrol. 2023. PMID: 37740193 Free PMC article.
Rituximab (RTX) and cyclophosphamide (CYC) based treatments are both recommended as first-line therapies in idiopathic membranous nephropathy (IMN) by KDIGO 2021 guideline. However, the efficacy of RTX vs. ...Eight studies involving 600 adult patients with IMN were …
Rituximab (RTX) and cyclophosphamide (CYC) based treatments are both recommended as first-line therapies in idiopathic membranous …
Combination of Rituximab and Low-dose Tacrolimus in the Treatment of Refractory Membranous Nephropathy: A Retrospective Cohort Study.
Chen X, Jiao S, Li S, Li J, Li P, Song F, Yan Z. Chen X, et al. Balkan Med J. 2023 Jul 12;40(4):287-293. doi: 10.4274/balkanmedj.galenos.2023.2022-9-7. Epub 2023 Jun 1. Balkan Med J. 2023. PMID: 37260416 Free PMC article.
BACKGROUND: Conventional regimens for refractory idiopathic membranous nephropathy (IMN) still have limitations. Rituximab (RTX) has a good effect in the treatment of refractory IMN. ...In the RTX group, RTX was given at the same dosage as the RTX + TAC group. Cl …
BACKGROUND: Conventional regimens for refractory idiopathic membranous nephropathy (IMN) still have limitations. Rituximab (RT …
Immunoadsorption in nephrotic syndrome: Where are we now and where are we going from here?
Kronbichler A, Gauckler P, Lee KH, Shin JI, Malvezzi P, Mayer G. Kronbichler A, et al. Atheroscler Suppl. 2019 Dec;40:55-60. doi: 10.1016/j.atherosclerosissup.2019.08.027. Epub 2019 Aug 17. Atheroscler Suppl. 2019. PMID: 31447217 Review.
Idiopathic nephrotic syndrome (INS) is characterized by three different entities, namely minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS) and membranous nephropathy (MN). While there is an increasing understanding of primary MN with the discov …
Idiopathic nephrotic syndrome (INS) is characterized by three different entities, namely minimal change disease (MCD), focal segmental glome …
Pathogenesis of membranous nephropathy: a new paradigm in evolution.
Glassock RJ. Glassock RJ. Contrib Nephrol. 2013;181:131-42. doi: 10.1159/000348472. Epub 2013 May 8. Contrib Nephrol. 2013. PMID: 23689575 Review.
Membranous nephropathy (MN) has been recognized as a distinct morphological entity for over 50 years, but it is only recently that the underlying pathogenesis of the primary form of the disorder has been elucidated. ...The autoimmune response is modulated by genes a …
Membranous nephropathy (MN) has been recognized as a distinct morphological entity for over 50 years, but it is only recently …
23 results